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Abstract
Oxidative stress (OS), the absence of equilibrium between prooxidants and antioxi-
dants in the body, has been shown to play a pivotal role in the initiation and pro-
gression of many diseases. Saffron has been noted for its antioxidant capacity and 
can be used to improve OS parameters in unhealthy patients. Our aim was to evalu-
ate the efficacy of saffron supplementation on OS parameters in unhealthy patients 
in randomized controlled trials (RCTs). We searched Medline, EMBASE, Cochrane 
CENTRAL, Scopus, and Web of Science without language restrictions for RCTs up 
until April 2021. Studies were included if they compared any form of saffron sup-
plementation to placebo or no supplementation on OS parameters in unhealthy pa-
tients. Using a random- effects model with calculated standardized mean difference 
(SMD) and 95% confidence intervals (CI), we quantitatively synthesized the data. 
Heterogeneity was assessed using Cochrane's I2 values. Ten randomized controlled 
trials were eligible for this review. Seven were included in the meta- analysis and in-
dicated an association between saffron intake and a statistically significant decrease 
in malondialdehyde (MDA) levels (SMD: −0.40; 95% CI: −0.63, −0.17; I2 = 32.6%) and 
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1  | INTRODUC TION
Oxidative stress (OS) describes a microenvironment manifested by 
an absence of equilibrium between prooxidants and antioxidants 
(Liguori et al., 2018). The most important prooxidant enzymes com-
prise xanthine oxidase (XO), nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase, and nitric oxide synthase (NOS), whereas 
the most important antioxidant enzymes are glutathione reductase 
(GR), glutathione peroxidase (GPx), superoxide dismutase- 1 (SOD- 1), 
and catalase (CAT, Akbari et al., 2020; Maciejczyk et al., 2018). The 
repercussion of OS is the development of a biologically destructive 
microenvironment enriched with free radicals, namely reactive ox-
ygen species (ROS) and reactive nitrogen species (RNS, Phaniendra 
et al., 2015). These free radicals can be generated in response to var-
ious endogenous sources, such as XO, NADPH, and NOS enzymes, 
and exogenous sources, such as pollution, medication, and radiation 
(Phaniendra et al., 2015). These free radicals play critical physiolog-
ical roles in cell signaling, immune defense, and energy extraction, 
and their deleterious effects are adequately counterbalanced by 
anti- oxidant machineries (Genestra, 2007). However, unneutral-
ized excessive free radicals culminate in OS, and consequently bring 
about tissue injury and cell death (Cooke et al., 2003). Biochemically, 
the most important OS damage products comprise malondialdehyde 
(MDA), 4- hydroxynonenal (4- HNE), and advanced glycation end 
product (AGE, Maciejczyk et al., 2018). Total antioxidant capacity 
(TAC) and total oxidant status (TOS) are the two most frequent bio-
chemical parameters employed to gauge the overall oxidant/anti- 
oxidant profile (Maciejczyk et al., 2018).
Current research highlights the pivotal, pathophysiologic role 
of OS in the initiation and progression of a wide array of disorders, 
such as hypertension (Rodrigo et al., 2011), diabetes mellitus (Asmat 
et al., 2016), obesity (Manna & Jain, 2015), metabolic syndrome 
(Mahjoub & Masrour- Roudsari, 2012), neurodegenerative disorders 
(Yaribeygi et al., 2018), cardiovascular disorders (Taleb et al., 2018), 
and malignancies (Hayes et al., 2020). Many factors, namely genetic, 
environmental, and dietary, can modulate the interplay between 
OS and the aforementioned disorders (Morvaridzadeh et al., 2020). 
Indeed, diet composition can considerably influence the OS microen-
vironment through the intrinsic prooxidant or antioxidant properties 
of such dietary elements (Namazi et al., 2018; Vetrani et al., 2013). 
Several dietary constituents have been greenlighted as naturally 
occurring antioxidants, such as cranberries (Blumberg et al., 2013) 
and a variety of spices, including garlic, ginger, and turmeric (Yashin 
et al., 2017).
Saffron, also known as Crocus sativus, is a common Mediterranean 
spice plant. It is composed of four key ingredients, namely cro-
cin, crocetin, picrocrocin, and safranal (Roshanravan et al., 2020). 
Previous meta- analyses have illustrated the beneficial effects of 
saffron on select blood pressure, glycemic, lipid, metabolic, and an-
thropometric indices (Asbaghi et al., 2019; Giannoulaki et al., 2020; 
Pourmasoumi et al., 2019; Rahmani et al., 2019; Roshanravan 
et al., 2020). A key property of saffron is its antioxidant capacity 
(Boskabady & Farkhondeh, 2016; Mashmoul et al., 2013). Several 
randomized controlled trials were carried out to examine the effect 
of saffron supplementation on mitigating OS (Ebrahimi et al., 2019; 
Hamidi et al., 2020; Karimi- Nazari et al., 2019). However, the OS out-
comes were inconsistent, as well as methodologically limited by small 
sample size, variable study duration, and heterogeneous underlying 
disorder. To the best of our knowledge, to date, no meta- analysis has 
been performed to pool evidence from randomized controlled trials 
(RCTs) to inform concrete dietary recommendations concerning saf-
fron supplementation and OS mitigation.
Thus, the goal of this research was to carry out a systematic re-
view and meta- analysis of all RCTs that evaluated the impact of saf-
fron supplementation on OS indices in unhealthy individuals.
2  | METHODS
2.1 | Data sources and search strategy
This systematic review and meta- analysis was performed according 
to The Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) guidelines (Moher et al., 2009). Searches were 
run in Medline, EMBASE, Cochrane CENTRAL, Scopus, and Web of 
Science without language restrictions for RCTs up until April 2021. 
Crosschecking references of relevant reviews was also performed. 
The main terms searched in the databases included: “Saffron OR 
Crocus sativus OR Safranal OR Crocin OR Crocetin OR Picrocrocin 
AND Oxidative Stress OR Total Antioxidant Capacity OR antioxidant 
OR Oxidant OR reactive oxygen species OR Catalase OR Oxygen 
Radical Absorbance OR reactive nitrogen species OR lipid peroxide 
OR Malondialdehyde OR Nitric oxide”. Details on the search strategy 
and syntaxes for individual databases can be found in Appendix 1.
a significant increase in total antioxidant capacity (TAC, SMD: 0.24; 95% CI: 0.05, 
0.42; I2 = 00.0%). Saffron intake was shown to significantly impact MDA and TAC, 
indicating its beneficial properties in improving OS in unhealthy patients. However, 
additional RCTs are required to evaluate the effect on other OS parameters.
K E Y W O R D S
malondialdehyde, oxidative stress, saffron, total antioxidant capacity
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2.2 | Selection criteria
We included randomized, placebo- controlled or crossover design tri-
als that compared any form of saffron supplementation versus no 
supplementation on OS parameters, namely TAC, MDA, GSH, GPx, 
SOD, NO, CAT, and isoprostanes, in unhealthy patients. Papers re-
porting sufficiently on outcomes comprised the difference in means 
with 95% confidence intervals (95% CI). Non- randomized studies 
(cross- sectional, case series, case studies, case– controls, and cohort 
studies) were excluded. We also excluded nonrandomized articles, 
abstracts, letters to the editor, in vitro and animal studies, and stud-
ies with less than one week of follow up after intervention. Table 1 
indicates the Cochrane's evidence- based PICO search criteria for 
this meta- analysis.
2.3 | Data extraction and statistical analysis
We extracted author details, general population characteristics, 
the dose of saffron, the kind of saffron supplement given, and main 
outcomes. Results were extracted in mean and standard deviation 
(SD). In order to calculate standard mean difference (SMD), results 
reported as standard error (SE), confidence interval, interquartile 
range (IQR), and the minimum and maximum value of each variable 
were converted to SD. We used STATA software version 11 (STATA 
Corp) and applied the random- effects model. Statistical significance 
was defined at p < .05.
Heterogeneity was assessed using chi- squared tests with sig-
nificant heterogeneity considered at a p- value <0.1 and I2 statistic 
around 25% (I2 = 25), 50% (I2 = 50), and 75% (I2 = 75), which would 
mean low, medium, and high heterogeneity, respectively(Huedo- 
Medina et al., 2006). Sensitivity analysis and funnel plots were used 
to evaluate the overall effect of each study. Funnel plots were used 
to visualize and evaluate publication error, and symmetry was ex-
amined using Egger's regression asymmetry test and Begg's rank 
correlation. Two researchers (JH and MM) independently performed 




The initial search of electronic databases yielded a total of 183 
studies. After removing duplicates, 124 unique records remained. 
After analyzing the titles and the abstracts, we concluded that 84 
additional articles did not fulfil our inclusion criteria. After full text 
screening, we excluded further 20 studies as they failed to report on 
variables of interest. Thus, 10 trials met the established criteria to be 
included in this systematic review and meta- analysis (Abedimanesh 
et al., 2020; Azimi et al., 2014; Ebrahimi et al., 2019; Ghaderi 
et al., 2019; Ghiasian et al., 2019; Hamidi et al., 2020; Karimi- Nazari 
et al., 2019; Pour et al., 2020; Shahbazian et al., 2019; Tahvilian 
et al., 2020). The flow diagram of study selection is presented in 
Figure 1.
3.2 | Characteristics of the included studies
Characteristics of the included trials are presented in Table 2. In 
total, 651 subjects were recruited in primary studies. Included arti-
cles were published between 2014 and 2020. The duration of sup-
plementation with saffron ranged between four and twelve weeks. 
Saffron dosage ranged from 30 to 1,000 mg/day. The sample size of 
the included trials ranged from 40 to 80 subjects. All included tri-
als were performed in Iran. The age of participants in included trials 
ranged from 31 to 57 years. The studies enrolled participants with 
type 2 diabetes (Azimi et al., 2014; Ebrahimi et al., 2019; Shahbazian 
et al., 2019), coronary artery disease (Abedimanesh et al., 2020), ul-
cerative sclerosis (Tahvilian et al., 2020), multiple sclerosis (Ghiasian 
et al., 2019), nonalcoholic fatty liver (Pour et al., 2020), rheumatoid 
arthritis (Hamidi et al., 2020), overweight/obese prediabetic patients 
(Karimi- Nazari et al., 2019), and methadone maintenance treatment 
patients (Ghaderi et al., 2019). In addition, articles were performed 
on subjects with various baseline body mass index (BMI) values; 
nine studies (Abedimanesh et al., 2020; Azimi et al., 2014; Ebrahimi 
et al., 2019; Ghaderi et al., 2019; Giannoulaki et al., 2020; Hamidi 
Domain Selection criteria
Participants Unhealthy adults >18 years old with any disease
Interventions Supplementation with any kind of saffron (Saffron OR Crocus sativus 
OR Safranal OR Crocin OR Crocetin OR Picrocrocin)
Comparators Placebo
No intervention
Outcomes Oxidative stress parameters, including TAC, MDA, GSH, GPx, SOD, 
NO, CAT, and isoprostanes
Study design Randomized controlled trials (including parallel or crossover studies)
Abbreviations: CAT, catalase activity; GPx, glutathione peroxidase activity; GSH, glutathione; 
MDA, malondialdehyde; NO, nitric oxide; SOD, superoxide dismutase; TAC, total antioxidant 
capacity.
TA B L E  1   PICO inclusion criteria
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et al., 2020; Karimi- Nazari et al., 2019; Milne et al., 2015; Pour 
et al., 2020; Shahbazian et al., 2019; Tahvilian et al., 2020) were con-
ducted on participants with a BMI over 25 kg/m2 up to 29.9 kg/m2, 
and one study did not report BMI (Ghiasian et al., 2019).
3.3 | Qualitative results
Several OS- related variables were assessed in the included tri-
als, however, due to the small number of studies, they were not 
included in the meta- analysis. The main results are summarized 
narratively. One study evaluated the effect of saffron intake on 
serum levels of oxidized low- density cholesterol (ox- LDL) as an OS 
indicator (Abedimanesh et al., 2020). Oxidized LDL is a marker of 
lipoprotein- related OS and a risk factor for cardiovascular diseases 
(Holvoet et al., 2008). Abedimanesh et al. indicated that saffron in-
take significantly reduces ox- LDL levels (Abedimanesh et al., 2020).
F2- isoprostanes from arachidonic acid are the most primary 
substances of lipid peroxidation and are one of the most reliable 
variables for assessing OS according to recent investigations (Milne 
et al., 2015). One of the included studies investigated the effect of 
saffron intake on F2- isoprostanes levels, and they reported that saf-
fron intake had no significant effect on F2- isoprostanes concentra-
tion (Azimi et al., 2014). Another finding of our primary studies was 
elevated levels of diphenyl pycryl hydrazyl (DPPH) radical scaveng-
ing activity after saffron intake, which can be explained by the fact 
that saffron can function as an antioxidant factor by donating a hy-
drogen atom to the DPPH radical anion (Karimi- Nazari et al., 2019).
F I G U R E  1   PRIMSA flow diagram
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3.4 | Meta- analysis
This meta- analysis included seven studies and indicated that the saffron 
intake was associated with a statistically significant decrease in MDA 
levels (SMD: −0.40; 95% CI: −0.63, −0.17; I2 = 32.6%, Figure 2) and a 
significant increase in TAC (SMD: 0.24; 95% CI: 0.05, 0.42; I2 = 00.0%, 
Figure 3). We performed a subgroup analysis based on disease type (met-
abolic vs. nonmetabolic), duration and dose of saffron intake, and age of 
participants. For patients to be considered as having a metabolic disease, 
one of the indicators of metabolic syndrome needed to be met: hyperlipi-
demia, hyperglycemia, hypertension, and obesity. The results of the sub-
group analysis showed that MDA decreased significantly in patients with 
nonmetabolic diseases and after a dose of over 50 mg/day compared to 
patients with metabolic diseases and doses of <50 mg/day. The subgroup 
analysis also revealed that saffron intake significantly increased TAC in 
nonmetabolic disease patients compared to metabolic patients. TAC 
was also significantly increased in patients in interventions of fewer than 
10 weeks duration compared to longer interventions. Further, saffron in-
take also significantly increased TAC in middle- aged adults compared to 
senior adults. Results of the subgroup analysis are presented in Table 3.
3.5 | Quality appraisal
The results of the risk of bias assessment are presented in Appendix 
2. Almost all included trials were rated at a low risk of bias for 
randomization, concealment, and blinding of participants and per-
sonnel. Further, five included studies were evaluated at an unclear 
risk for incomplete outcome data, and six of trials were rated at un-
clear risk for reporting bias. Three of included studies were rated 
unclear for other potential sources of biases.
4  | DISCUSSION
To the best of my knowledge, this is the first comprehensive sys-
tematic review and meta- analysis that investigated the impact 
of saffron supplementation on OS parameters. Saffron is widely 
used for many purposes, including medicinal applications, due 
to its complex composition of flavoring, aromatic, and colorful 
substances that are associated with health- promoting benefits. 
Saffron compounds with higher biological activity include crocin, 
crocetin, picrocrocin, and safranal (Melnyk et al., 2010). In addi-
tion to the broad ancient uses of saffron for medicinal purposes, 
several studies have demonstrated that saffron has antioxidant, 
anti- inflammatory, anticancer, antidepressant, and antiplatelet 
effects which suggest that saffron may be a potential therapeutic 
agent in many diseases, such as neurodegenerative diseases, dia-
betes mellitus, atherosclerosis, cancer, and sexual dysfunction, 
among others (Christodoulou et al., 2015; Leone et al., 2018; 
Razavi & Hosseinzadeh, 2017; Schmidt et al., 2007; Shakeri 
et al., 2020).
F I G U R E  2   Forest plot showing the summary effect size for MDA levels between saffron and placebo groups
NOTE: Weights are from random effects analysis
Overall  (I-squared = 32.6%, p = 0.179)
Ghiasian et al (2019)
Shahbazian et al (2019)
ID
Ghaderi et al (2019)
Hamidi et al (2020)
Tahvillian et al (2020)
Study
Ebrahimi et al (2020)
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The major components of saffron have been studied in animal 
and cellular models and have been shown to have positive effects 
on the level and activity of enzymes involved in cellular antioxidant 
activity, such as CAT and SOD. Meanwhile, the levels of recognized 
markers of OS, such as MDA (an indicator of the peroxidation of 
lipids), were shown to be decreased after treatment with saffron 
constituents (reviewed in Lopresti & Drummond, 2014; Yousefi 
et al., 2020).
The total antioxidant status of an individual may also be evalu-
ated by measuring the TAC, as initially proposed by Miller et al.,1993. 
This parameter is easily determined and can be applied in many clin-
ical contexts to evaluate the TAC of foods, as many nutrients have 
been recognized by their role as antioxidants (reviewed in Kaliora & 
Dedoussis, 2007; Kusano & Ferrari, 2008). Our study evaluated the 
clinical context of the effect of saffron consumption on OS markers, 
and mainly focused on the results obtained for MDA and TAC lev-
els. The seven trials included in the meta- analysis indicated that the 
intake of saffron significantly decreased serum MDA and increased 
TAC (Figures 2 and 3), which highlights the positive effect that saf-
fron appears to exhibit on OS.
Oxidative stress is associated with a wide range of diseases, such 
as diabetes mellitus and metabolic syndrome (including hyperlipid-
emia, hyperglycemia, hypertension, and obesity), which all of which 
are risk factors for cardiovascular diseases (Denisenko et al., 2020; 
Gil- del Valle et al., 2005). To date, several studies have been carried 
out to evaluate the effect of saffron on different OS markers in these 
aforementioned diseases and others (Razavi & Hosseinzadeh, 2017; 
Pour et al., 2020). For example, in patients with nonalcoholic fatty 
liver disease, the ingestion of 100 mg saffron per day for 12 weeks 
induced a significant increase in TAC and decrease in MDA levels 
(Pour et al., 2020) while the intake of 15 mg of crocin twice a day 
for 8 weeks induced a significant reduction of the pro- oxidant- anti- 
oxidant balance, in patients with metabolic syndrome (Nikbakht- Jam 
et al., 2016).
Recent systematic reviews and meta- analyses have highlighted 
a possible positive effect of saffron against cardiovascular diseases 
and as a modulator of serum lipid profile, showing that saffron 
can lead to decreases in serum total cholesterol and triglyceride 
concentrations, as well as an increase in high- density lipoprotein 
levels. However, these results were based on a limited number of 
trials and should be interpreted with caution (Asbaghi et al., 2019; 
Pourmasoumi et al., 2019; Rahmani et al., 2019; Roshanravan 
et al., 2020).
Several other studies have shown that saffron or its biologically 
active components may have a positive impact on several parame-
ters related to glucose metabolism, in patients with different non- 
communicable diseases, and in patients undergoing hypoglycemic 
treatment, despite some discrepancies in the obtained conclu-
sions. For example, saffron intake was shown to decrease fasting 
blood glucose (FBG), fasting insulin, and, for longer interventions, 
decrease HbA1c in one study (Sohaei et al., 2019). However, in an-
other analysis, the effect on FBG was similar but more significant 
for interventions carried out for periods of 12 weeks or more, while 
no significant effect was observed in HbA1c (Rahmani et al., 2020). 
F I G U R E  3   Forest plot showing the summary effect size for TAC levels between saffron and placebo groups
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.448)
Ghaderi et al (2019)
Ebrahimi et al (2020)
ID
Tahvillian et al (2020)
Hamidi et al (2020)
Shahbazian et al (2019)
Ghiasian et al (2019)
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The intake of crocin was also evaluated and may also reduce FBG 
(Naserizadeh et al., 2020). In addition, another recent meta- analysis 
focusing solely on patients with diabetes mellitus or metabolic 
syndrome assessed the effects of either saffron or its component, 
crocin, on several outcomes related to the metabolic profile of the 
patients. The authors concluded that although saffron appears to 
be an important regulator of FBG, however, most trials carried out 
thus far are not robust enough to clearly state the impact of saffron 
on these patients (Giannoulaki et al., 2020). These contradictory re-
sults may be due to the fact that saffron components are difficult to 
absorb by the human body and act only in the gastrointestinal tract 
(Naserizadeh et al., 2020). It is clear in all reported results that all 
the findings need to be carefully interpreted as the different trials 
included present high levels of heterogeneity at several levels.
The results obtained after the subgroup analysis depicted statis-
tically significant positive effects of saffron for both MDA and TAC 
levels in patients with non- metabolic diseases. Additionally, when el-
evated doses of saffron were used (50 mg/day or more) or in shorter 
interventions (fewer than 10 weeks), similar results were observed 
for MDA and TAC levels, respectively (Table 3). In this analysis, the 
age of the participants was determined to be another important 
factor to consider when assessing the health benefits of saffron, 
as TAC levels increased for younger patients (middle age vs. senior 
adults, Table 3). Several possible mechanisms could be responsible 
for the beneficial effect of saffron on improving OS parameters. It 
has recently been shown that saffron may affect cardiometabolic 
outcomes through its effect on non- coding RNAs, such as microR-
NAs (miRNAs, Ahmadi Khatir et al., 2018). MiRNAs are endogenous 
∼23- nucleotide RNAs that can bind to different locations on mRNAs 
of protein- coding genes to modulate expression of these genes 
(Emami, Akbari, et al., 2019, Emami, Nekouian, et al., 2019; Talebi 
et al., 2020). MicroRNAs are also known to impact the stability and 
evolution of several mRNAs (Akbari et al., 2016; Zamani et al., 2019). 
It has also been demonstrated that saffron may affect up- stream 
genes related to OS, such as Nrf2 and MAPK, through changes in 
miRNAs (Ashrafizadeh et al., 2020; Hassani et al., 2017).
Although the results on the effects of saffron against OS are prom-
ising, several factors should also be considered when interpreting the 
available data. Plants’ composition and quality vary with the methods 
used for cultivation, production, and extraction, affecting the possi-
ble outcomes and their reproducibility (Moratalla- Lopez et al., 2021; 
Schmidt et al., 2007). Additionally, the means of saffron or its com-
ponents consumption may also affect bioavailability, which may also 
affect the health benefits being evaluated. More studies are needed 
to fully understand how saffron and its constituents are absorbed and 
reach the cells to exert their effect (Giannoulaki et al., 2020).
TA B L E  3   Subgroup analysis assessing the effect of saffron intake on MDA and TAC
Variable Sub- grouped by No. of arms Effect size (SMD) 95% CI I2 (%)
p for 
heterogeneity
MDA Disease type Metabolicb  3 0.25 −0.52, 0.02 00.0 0.637
Non- 
Metabolic
4 −0.55 −0.94, −0.17a  51.3 0.104
Duration ≥10 weeks 4 −0.28 −0.51, 
−0.04a 
00.0 0.787
<10 weeks 3 0.64 −0.18, −0.10a  64.8 0.059
Saffron dosage ≥50 mg/day 4 −0.34 −0.56, −0.11a  00.0 0.980
<50 mg/day 3 −0.57 −1.24, 0.10 75.8 0.016





4 −0.52 −0.92, −0.13a  56.5 0.075
TAC Disease type Metabolicb  3 0.16 −0.22, 0.54 50.1 0.135
Non- 
Metabolic
4 0.31 0.05, 0.57a  00.0 0.776
Duration ≥10 weeks 4 0.16 −0.11, 0.43 25.3 0.260
<10 weeks 3 0.36 0.06, 0.67a  00.0 0.690
Saffron dosage ≥50 mg/day 4 0.21 −0.04, 0.47 16.9 0.307
<50 mg/day 3 0.28 −0.04, 0.60 02.5 0.359
Age Senior adults 3 0.03 −0.24, 0.30 00.0 0.730
Middle- age 
adults
4 0.41 0.16, 0.67a  00.0 0.774
Abbreviations: CI, confidence interval; MDA, malondialdehyde; SMD, standard mean difference; TAC, total antioxidant capacity.
aStatistically significant.
bAccording to metabolic syndrome components.
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Additional parameters that need to be taken in consideration 
include the amount of saffron ingested, the duration of the in-
tervention, and the number of patients enrolled in each trial. 
The studies available and included in this work were all carried 
out with small groups of patients, weakening the statistical value 
of the results. As discussed by Kaliora and Dedoussis (Kaliora & 
Dedoussis, 2007), the characteristics of the studied patients (e.g., 
age, sex, ethnicity, body mass index, initial total antioxidant status, 
and diet consumed) should also be considered carefully. For exam-
ple, this meta- analysis only includes studies that were carried out in 
Iran, which limits the possible extrapolation of the results for other 
populations. Another limitation of this review is that we didn't reg-
ister the protocol in advance. Further, when studying unhealthy 
subjects, different trials may be needed for different diseases. The 
stage of the disease, the medication administered, and additional 
factors that may contribute to improving the outcomes evaluated 
need to be identified so they do not interfere with the final results. 
More studies should be carried out addressing these questions to 
increase the current knowledge base about the health benefits of 
saffron on different illnesses.
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